<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><description>佰傲谷致力于打造一个垂直于生物制品领域的第三方平台。为生物制药企业提供品牌推广、技术咨询、项目交易、企业合作、人才培养等服务。为生物制药行业从业人员提供沟通交流、会议培训、工作求职、个人展示平台。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 14 Apr 2021 13:23:26 +0800</pubDate><image><url>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</url><title>佰傲谷BioValley | wechat-feeds</title><link>http://MzU1NTg4OTM3Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>专访丨艺妙神州联合创始人&amp;CTO齐菲菲： 百舟竞流，何以争锋？—CAR-T新锐的成长解读</title><link>https://mp.weixin.qq.com/s/rNzsrdzroB86_mCIH3V-Ug</link><description></description><content:encoded><![CDATA[专访丨艺妙神州联合创始人&CTO齐菲菲： 百舟竞流，何以争锋？—CAR-T新锐的成长解读]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item><item><title>今日直播 | 逆流而上的抗改</title><link>https://mp.weixin.qq.com/s/KMtMn_MAGNNXj073snSXXw</link><description></description><content:encoded><![CDATA[今日直播 | 逆流而上的抗改]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item><item><title>再爆&#34;罕见血栓&#34;，CDC和FDA呼吁暂停接种强生新冠腺病毒载体疫苗</title><link>https://mp.weixin.qq.com/s/DC6g3u_cya08nAQRK5QjJA</link><description></description><content:encoded><![CDATA[再爆"罕见血栓"，CDC和FDA呼吁暂停接种强生新冠腺病毒载体疫苗]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item><item><title>20位前FDA/NMPA审评专家将联袂上演新药中美欧多报大片</title><link>https://mp.weixin.qq.com/s/2z7H5ArxVUL0k2GaU7vgKw</link><description></description><content:encoded><![CDATA[20位前FDA/NMPA审评专家将联袂上演新药中美欧多报大片]]></content:encoded><pubDate>Wed, 14 Apr 2021 12:06:15 +0800</pubDate></item><item><title>同是天涯人--艾伯维、礼来之后，辉瑞两款JAK抑制剂遭FDA延期</title><link>https://mp.weixin.qq.com/s/-Vz_h8idQYlbVyjVRKf7-g</link><description></description><content:encoded><![CDATA[同是天涯人--艾伯维、礼来之后，辉瑞两款JAK抑制剂遭FDA延期]]></content:encoded><pubDate>Tue, 13 Apr 2021 11:33:52 +0800</pubDate></item><item><title>火热报名中 | 2021PVcon生物制品安全与工艺大会</title><link>https://mp.weixin.qq.com/s/P4PFdKy0uxS5ZdKzNYZK0Q</link><description></description><content:encoded><![CDATA[火热报名中 | 2021PVcon生物制品安全与工艺大会]]></content:encoded><pubDate>Tue, 13 Apr 2021 11:33:52 +0800</pubDate></item><item><title>2021 AACR|百济神州PD-1单抗再传佳绩，两项研究闪亮登场</title><link>https://mp.weixin.qq.com/s/WoLll0xxJnuhomLqMoJGPA</link><description></description><content:encoded><![CDATA[2021 AACR|百济神州PD-1单抗再传佳绩，两项研究闪亮登场]]></content:encoded><pubDate>Tue, 13 Apr 2021 11:33:52 +0800</pubDate></item><item><title>首款TF-ADC药物上市申请获FDA优先审查</title><link>https://mp.weixin.qq.com/s/0SDZMNQmMTJJ61cJ40e6Rg</link><description></description><content:encoded><![CDATA[首款TF-ADC药物上市申请获FDA优先审查]]></content:encoded><pubDate>Tue, 13 Apr 2021 11:33:52 +0800</pubDate></item><item><title>国内mRNA制药行业崛起进行时</title><link>https://mp.weixin.qq.com/s/iMsDTa9E0QJV5h9seodGqg</link><description></description><content:encoded><![CDATA[国内mRNA制药行业崛起进行时]]></content:encoded><pubDate>Tue, 13 Apr 2021 11:33:52 +0800</pubDate></item><item><title>抓住质量管理“牛鼻子“，你在哪一段？</title><link>https://mp.weixin.qq.com/s/2aZoEQosHPiQp5ZOukMeGg</link><description></description><content:encoded><![CDATA[抓住质量管理“牛鼻子“，你在哪一段？]]></content:encoded><pubDate>Tue, 13 Apr 2021 11:33:52 +0800</pubDate></item><item><title>创新药“卖水人”生死竞速，一触即发！</title><link>https://mp.weixin.qq.com/s/QLC57U_0dWeegfoDQfuFpQ</link><description></description><content:encoded><![CDATA[创新药“卖水人”生死竞速，一触即发！]]></content:encoded><pubDate>Mon, 12 Apr 2021 11:44:47 +0800</pubDate></item><item><title>2021AACR年会盛大开幕，众多药企亮相发声</title><link>https://mp.weixin.qq.com/s/2bB1z3ObLd5em5p9V5-zTw</link><description></description><content:encoded><![CDATA[2021AACR年会盛大开幕，众多药企亮相发声]]></content:encoded><pubDate>Mon, 12 Apr 2021 11:44:47 +0800</pubDate></item><item><title>IgA：粘膜抗感染免疫与炎症性疾病</title><link>https://mp.weixin.qq.com/s/MsrDL5TQavg5UJjoO9q6KQ</link><description></description><content:encoded><![CDATA[IgA：粘膜抗感染免疫与炎症性疾病]]></content:encoded><pubDate>Mon, 12 Apr 2021 11:44:47 +0800</pubDate></item><item><title>招聘 | 复宏汉霖 |工艺验证经理、生产支持制剂经理等</title><link>https://mp.weixin.qq.com/s/utGfYni3x9EBC3eVIXO2Pw</link><description></description><content:encoded><![CDATA[招聘 | 复宏汉霖 |工艺验证经理、生产支持制剂经理等]]></content:encoded><pubDate>Mon, 12 Apr 2021 11:44:47 +0800</pubDate></item><item><title>靶点药讯55|国内首款Muc1 ADC临床申请获NMPA、新型抗真菌药获批3期临床</title><link>https://mp.weixin.qq.com/s/HCBUEebQHjVmteqbwNpR2w</link><description></description><content:encoded><![CDATA[靶点药讯55|国内首款Muc1 ADC临床申请获NMPA、新型抗真菌药获批3期临床]]></content:encoded><pubDate>Sun, 11 Apr 2021 09:33:25 +0800</pubDate></item><item><title>全球最新生物制品质量法规追踪</title><link>https://mp.weixin.qq.com/s/EV55kbwnGxLrWFVWjOpZag</link><description></description><content:encoded><![CDATA[全球最新生物制品质量法规追踪]]></content:encoded><pubDate>Sun, 11 Apr 2021 09:33:25 +0800</pubDate></item><item><title>3月盘点——肿瘤领域FDA、NMPA获批新药有哪些？</title><link>https://mp.weixin.qq.com/s/QCNSpkD4Zps0dzmDOKg6RA</link><description></description><content:encoded><![CDATA[3月盘点——肿瘤领域FDA、NMPA获批新药有哪些？]]></content:encoded><pubDate>Sun, 11 Apr 2021 09:33:25 +0800</pubDate></item><item><title>斯微生物2021招聘开始啦</title><link>https://mp.weixin.qq.com/s/0PwC0eu4tWK92P2KrBwGMA</link><description></description><content:encoded><![CDATA[斯微生物2021招聘开始啦]]></content:encoded><pubDate>Sun, 11 Apr 2021 09:33:25 +0800</pubDate></item><item><title>ICH中国进程与展望，4月再次加速接轨，内含最新指南汇总！</title><link>https://mp.weixin.qq.com/s/oWFu-oXe5I9rieO3KugsuQ</link><description></description><content:encoded><![CDATA[ICH中国进程与展望，4月再次加速接轨，内含最新指南汇总！]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:35 +0800</pubDate></item><item><title>顺利收官 | TG-Bio第二届免疫治疗技术大会精彩回顾</title><link>https://mp.weixin.qq.com/s/f3wwLoTxK021ztoJ2j8V-Q</link><description></description><content:encoded><![CDATA[顺利收官 | TG-Bio第二届免疫治疗技术大会精彩回顾]]></content:encoded><pubDate>Sat, 10 Apr 2021 20:40:35 +0800</pubDate></item></channel></rss>